After the chemotherapy: Potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukemia in childhood

Frontiers in Pharmacology

Volumn 4 APR, Issue , 2013, Pages

  Scheede Bergdahl, Celena ^a,b   Thomas Jagoe, R ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Acute lymphoblastic leukemia; Cancer survivors; Chemotherapy; Motor neurons; Muscle dysfunction; Muscle mitochondria; Muscle satellite cells; Skeletal muscle

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; IMATINIB; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD LEUKEMIA; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; MITOCHONDRION; MOTONEURON; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE FUNCTION; MUSCLE GROWTH; MUSCLE INJURY; MUSCLE MOTOR NEURON; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYOPATHY; OBESITY; SATELLITE CELL;

EID: 84881525903     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00049     Document Type: Article

References (75)

1. Aslett, H., Levitt, G., Richardson, A., and Gibson, F. (2007). A review of long-term follow-up for survivors of childhood cancer. Eur. J. Cancer 43, 1781-1790.
2. Baehr, L. M., Furlow, J. D., and Bodine, S. C. (2011). Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. J. Physiol. 589, 4759-4776.
3. Balayssac, D., Ferrier, J., Descoeur, J., Ling, B., Pezet, D., Eschalier, A., et al. (2011). Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin. Drug Saf. 10, 407-417.
4. Barja, G., and Herrero, A. (2000). Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB J. 14, 312-318.
5. Batchelor, T. T., Taylor, L. P., Thaler, H. T., Posner, J. B., and DeAngelis, L. M. (1997). Steroid myopathy in cancer patients. Neurology 48, 1234-1238.
6. Bentzinger, C. F., Wang, Y. X., and Rudnicki, M. A. (2012). Building muscle: molecular regulation of myogenesis. Cold Spring Harb. Perspect. Biol. 4, pii: a008342.
7. Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., and St Clair, D. K. (2007). Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol. Interv. 7, 147-156.
8. Curry, H. L., Parkes, S. E., Powell, J. E., and Mann, J. R. (2006). Caring for survivors of childhood cancers: the size of the problem. Eur. J. Cancer 42, 501-508.
9. Davis, T. A., and Fiorotto, M. L. (2009). Regulation of muscle growth in neonates. Curr. Opin. Clin. Nutr. Metab. Care 12, 78-85.
10. Deschenes, M. R. (2004). Effects of aging on muscle fibre type and size. Sports Med. 34, 809-824.
11. Doria, E., Buonocore, D., Focarelli, A., and Marzatico, F. (2012). Relationship between human aging muscle and oxidative system pathway. Oxid. Med. Cell. Longev. 2012, 830257.
12. Duchateau, J., Semmler, J. G., and Enoka, R. M. (2006). Training adaptations in the behavior of human motor units. J. Appl. Physiol. 101, 1766-1775.
13. Ewer, M. S., and Ewer, S. M. (2010). Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7, 564-575.
14. Florin, T. A., Fryer, G. E., Miyoshi, T., Weitzman, M., Mertens, A. C., Hudson, M. M., et al. (2007). Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Cancer Epidemiol. Biomarkers Prev. 16, 1356-1363.
15. García, A., Calleja, J., Antolín, F. M., and Berciano, J. (2000). Peripheral motor and sensory nerve conduction studies in normal infants and children. Clin. Neurophysiol. 111, 513-520.
16. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-741.
17. Gilliam, L. A. A., and St Clair, D. K. (2011). Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid. Redox Signal. 15, 2543-2563.
18. Gilliam, L. A. A., Ferreira, L. F., Bruton, J. D., Moylan, J. S., Westerblad, H., St Clair, D. K., et al. (2009). Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J. Appl. Physiol. 107, 1935-1942.
19. Gilliam, L. A. A., Moylan, J. S., Patterson, E. W., Smith, J. D., Wilson, A. S., Rabbani, Z., et al. (2012). Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 302, C195-C202.
20. Harten, G., Stephani, U., Henze, G., Langermann, H. J., Riehm, H., and Hanefeld, F. (1984). Slight impairment of psychomotor skills in children after treatment of acute lymphoblastic leukemia. Eur. J. Pediatr. 142, 189-197.
21. Hovi, L., Era, P., Rautonen, J., and Siimes, M. A. (1993). Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 72, 276-281.
22. Ito, H., Miller, S., Billingham, M., Akimoto, H., Torti, S. V., Wade, R., et al. (1990). Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 87, 4275-4279.
23. Jackson, S. P., and Bartek, J. (2009). The DNA-damage response in human biology and disease. Nature 461, 1071-1078.
24. Järvelä, L. S., Niinikoski, H., Lähteenmäki, P. M., Heinonen, O. J., Kapanen, J., Arola, M., et al. (2010). Physical activity and fitness in adolescent and young adult long-term survivors of childhood acute lymphoblastic leukaemia. J. Cancer Surviv. 4, 339-345.
25. Jordan, K., Roila, F., Molassiotis, A., Maranzano, E., Clark-Snow, R. A., Feyer, P., et al. (2011). Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support. Care Cancer 19(Suppl. 1), S37-S42.
26. Jordan, M. A., Himes, R. H., and Wilson, L. (1985). Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 45, 2741-2747.
27. Kawano, F., Takeno, Y., Nakai, N., Higo, Y., Terada, M., Ohira, T., et al. (2008). Essential role of satellite cells in the growth of rat soleus muscle fibers. Am. J. Physiol. Cell Physiol. 295, C458-C467.
28. Kuang, S., Chargé, S. B., Seale, P., Huh, M., and Rudnicki, M. A. (2006). Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis. J. Cell Biol. 172, 103-113.
29. Kulkarni, K., Stobart, K., Witol, A., and Rosychuk, R. J. (2011). Leukemia and lymphoma incidence in children in Alberta, Canada: a population-based 22-year retrospective study. Pediatr. Hematol. Oncol. 28, 649-660.
30. Lax, N. Z., Turnbull, D. M., and Reeve, A. K. (2011). Mitochondrial mutations: newly discovered players in neuronal degeneration. Neuroscientist 17, 645-658.
31. Lebrecht, D., Kokkori, A., Ketelsen, U.-P., Setzer, B., and Walker, U. A. (2005). Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J. Pathol. 207, 436-444.
32. Lebrecht, D., Setzer, B., Ketelsen, U. P., Haberstroh, J., and Walker, U. A. (2003). Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108, 2423-2429.
33. Lebrecht, D., Setzer, B., Rohrbach, R., and Walker, U. A. (2004). Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol. Dial. Transplant. 19, 329-336.
34. Lee, H. J., Oran, B., Saliba, R. M., Couriel, D. M., Shin, K., Massey, P., et al. (2006). Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant. 38, 299-303.
35. Lexell, J., Sjöström, M., Nordlund, A. S., and Taylor, C. C. (1992). Growth and development of human muscle: a quantitative morphological study of whole vastus lateralis from childhood to adult age. Muscle Nerve 15, 404-409.
36. Marzetti, E., Hwang, J. C. Y., Lees, H. A., Wohlgemuth, S. E., Dupont-Versteegden, E. E., Carter, C. S., et al. (2010). Mitochondrial death effectors: relevance to sarcopenia and disuse muscle atrophy. Biochim. Biophys. Acta 1800, 235-244.
37. McComas, A. J., Galea, V., and de Bruin, H. (1993). Motor unit populations in healthy and diseased muscles. Phys. Ther. 73, 868-877.
38. Medikayala, S., Piteo, B., Zhao, X., and Edwards, J. G. (2011). Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. Am. J. Physiol. Cell Physiol. 300, C338-C348.
39. Menconi, M., Fareed, M., O'Neal, P., Poylin, V., Wei, W., and Hasselgren, P.-O. (2007). Role of glucocorticoids in the molecular regulation of muscle wasting.Crit. Care Med. 35, S602-S608.
40. Mitsui, T., Azuma, H., Nagasawa, M., Iuchi, T., Akaike, M., Odomi, M., et al. (2002). Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J. Neurol. 249, 1004-1009.
41. Moore, A., and Pinkerton, R. (2009). Vincristine: can its therapeutic index be enhanced? Pediatr. Blood Cancer 53, 1180-1187.
42. Morales-Polanco, M., Javier Jímenez-Balderas, F., Butrón, L., Gutiérrez, L., and Paredes-González, E. (1997). Rhabdomyolysis in patients with acute lymphoblastic leukemia. Arch. Med. Res. 28, 377-381.
43. Nagarajan, R., Kamruzzaman, A., Ness, K. K., Marchese, V. G., Sklar, C., Mertens, A., et al. (2011). Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer 117, 625-634.
44. Ness, K. K., Baker, K. S., Dengel, D. R., Youngren, N., Sibley, S., Mertens, A. C., et al. (2007). Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 49, 975-981.
45. Ness, K. K., Hudson, M. M., Pui, C.-H., Green, D. M., Krull, K. R., Huang, T. T., et al. (2012). Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer 118, 828-838.
46. Ness, K. K., Mertens, A. C., Hudson, M. M., Wall, M. M., Leisenring, W. M., Oeffinger, K. C., et al. (2005). Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann. Intern. Med. 143, 639-647.
47. Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., and Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J. Mol. Cell Cardiol. 52, 1213-1225.
48. Oeffinger, K. C. (2003). Longitudinal risk-based health care for adult survivors of childhood cancer. Curr. Probl. Cancer 27, 143-167.
49. Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., et al. (2006). Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572-1582.
50. Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Yasui, Y., Fears, T., Stovall, M., et al. (2003). Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 21, 1359-1365.
51. Oeffinger, K. C., Nathan, P. C., and Kremer, L. C. M. (2010). Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Hematol. Oncol. Clin. North Am. 24, 129-149.
52. Pallafacchina, G., François, S., Regnault, B., Czarny, B., Dive, V., Cumano, A., et al. (2010). An adult tissue-specific stem cell in its niche: a gene profiling analysis of in vivo quiescent and activated muscle satellite cells. Stem Cell Res. 4, 77-91.
53. Pansters, N. A., Langen, R. C., Wouters, E., and Schols, A. M. (2012). Synergistic stimulation of myogenesis by glucocorticoid and IGF-I signaling. J. Appl. Physiol. doi: 10.1152/japplphysiol.00503.2012 [Epub ahead of print].
54. Park, C. B., and Larsson, N.-G. (2011). Mitochondrial DNA mutations in disease and aging. J. Cell Biol. 193, 809-818.
55. Paus, T., Zijdenbos, A., Worsley, K., Collins, D. L., Blumenthal, J., Giedd, J. N., et al. (1999). Structural maturation of neural pathways in children and adolescents: in vivo study. Science 283, 1908-1911.
56. Prasad, P. K., Bowles, T., and Friedman, D. L. (2010). Is there a role for a specialized follow-up clinic for survivors of pediatric cancer? Cancer Treat. Rev. 36, 372-376.
57. Pui, C.-H., and Evans, W. E. (2006). Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166-178.
58. Rives, S., Estella, J., Gómez, P., López-Duarte, M., de Miguel, P. G., Verdeguer, A., et al. (2011). Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br. J. Haematol. 154, 600-611.
59. Rosenthal, S., and Kaufman, S. (1974). Vincristine neurotoxicity. Ann. Intern. Med. 80, 733-737.
60. Ryan, J. R., and Emami, A. (1983). Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia. Cancer 51, 423-425.
61. Schakman, O., Gilson, H., and Thissen, J. P. (2008). Mechanisms of glucocorticoid-induced myopathy. J. Endocrinol. 197, 1-10.
62. Serrano, J., Palmeira, C. M., Kuehl, D. W., and Wallace, K. B. (1999). Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim. Biophys. Acta 1411, 201-205.
63. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29.
64. Skinner, R. (2012a). Long-term effects of cancer therapy in children - organs, systems and tissues. Paediatr. Child Health (Oxford) 22, 201-206.
65. Skinner, R. (2012b). Long-term effects of cancer therapy in children - functional effects, late mortality and long-term follow-up. Paediatr. Child Health (Oxford) 22, 248-252.
66. Talvensaari, K. K., Jämsen, A., Vanharanta, H., and Lanning, M. (1995). Decreased isokinetic trunk muscle strength and performance in long-term survivors of childhood malignancies: correlation with hormonal defects. Arch. Phys. Med. Rehabil. 76, 983-988.
67. Talvensaari, K. K., Lanning, M., Tapanainen, P., and Knip, M. (1996). Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J. Clin. Endocrinol. Metab. 81, 3051-3055.
68. Vainionpää, L. (1993). Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment. Eur. J. Pediatr. 152, 115-119.
69. van Brussel, M., Takken, T., van der Net, J., Engelbert, R. H., Bierings, M., Schoenmakers, M. A., et al. (2006). Physical function and fitness in long-term survivors of childhood leukaemia. Pediatr. Rehabil. 9, 267-274.
70. van der Sluis, I. M., van den Heuvel-Eibrink, M. M., Hählen, K., Krenning , E. P., and de Muinck Keizer-Schrama, S. M. (2002). Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J. Pediatr. 141, 204-210.
71. van Norren, K., van Helvoort, A., Argilés, J. M., van Tuijl, S., Arts, K., Gorselink, M., et al. (2009). Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br. J. Cancer 100, 311-314.
72. Wardell, T. M., Ferguson, E., Chinnery, P. F., Borthwick, G. M., Taylor, R. W., Jackson, G., et al. (2003). Changes in the human mitochondrial genome after treatment of malignant disease. Mutat. Res. 525, 19-27.
73. Warner, J. T. (2008). Body composition, exercise and energy expenditure in survivors of acute lymphoblastic leukaemia. Pediatr. Blood Cancer 50, 456-461.
74. Wright, M. J., Halton, J. M., Martin, R. F., and Barr, R. D. (1998). Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med. Pediatr. Oncol. 31, 86-90.
75. Zuelzer, W. W. (1964). Implications of long-term survival in acute stem cell leukemia of childhood treated with composite cyclical therapy. Blood 24, 477-494.